MusclePharm (OTCMKTS:MSLP) & Orgenesis (NASDAQ:ORGS) Head to Head Survey

Profitability

This table compares MusclePharm and Orgenesis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MusclePharm	-38.51%	N/A	-169.56%
Orgenesis	-3,827.81%	N/A	-130.18%

Valuation and Earnings

This table compares MusclePharm and Orgenesis”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MusclePharm	$50.04 million	0.00	-$12.87 million	($0.58)	N/A
Orgenesis	$662,000.00	4.61	-$55.36 million	($11.51)	-0.05

MusclePharm has higher revenue and earnings than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than MusclePharm, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

15.5% of MusclePharm shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 60.7% of MusclePharm shares are held by company insiders. Comparatively, 1.9% of Orgenesis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

MusclePharm has a beta of -0.07, suggesting that its share price is 107% less volatile than the S&P 500. Comparatively, Orgenesis has a beta of 3.06, suggesting that its share price is 206% more volatile than the S&P 500.

Summary

MusclePharm beats Orgenesis on 6 of the 9 factors compared between the two stocks.

About MusclePharm

MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.

About Orgenesis

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.